PRESS RELEASE: Xanodyne Pharmaceuticals Files to Go Public

Xanodyne Pharmaceuticals Files to Go Public

NEWPORT, Ky. -- Xanodyne Pharmaceuticals, Inc. announced today that it has filed a registration statement with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. All of the shares in the proposed offering will be sold by Xanodyne.

Morgan Stanley & Co. Incorporated is acting as sole bookrunning manager for the offering. Deutsche Bank Securities Inc. is co-lead manager, and RBC Capital Markets and Natixis Bleichroeder Inc. are co-managers.

Xanodyne is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women’s healthcare and pain management. Xanodyne markets a portfolio of revenue generating products and is advancing a late stage pipeline of product candidates targeted at significant potential markets in its focus areas.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective.

The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to this offering may be obtained by contacting Morgan Stanley & Co. Incorporated, 180 Varick Street, New York, New York 10014, Attention: Prospectus Department, or by email at [email protected].

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.